ELIGIBILITY
1. The candidate must meet the eligibility prerequisites for Fellowship outlined in the Fellowship Candidate Handbook.
2. Membership of the College, in Small Animal Medicine, must be achieved prior to the Fellowship examination.

OBJECTIVES
To demonstrate that the candidate has attained sufficient knowledge, training, experience and accomplishment to meet the criteria for registration as a Specialist in Veterinary Medical Oncology.

LEARNING OUTCOMES
1. The candidate will have a detailed\(^1\) knowledge of:
   
   1.1. The aetiopathogenesis, epidemiology, pathology, diagnosis, treatment and management measures for oncological diseases of cats and dogs
   
   1.2. Physical, chemical and viral carcinogenesis and the cellular and molecular or biological mechanisms of tumour development, progression and metastasis

---

\(^1\) **Knowledge levels:**

**Detailed knowledge** — candidates must be able to demonstrate an in-depth knowledge of the topic including differing points of view and published literature. The highest level of knowledge.

**Sound knowledge** — candidate must know all of the principles of the topic including some of the finer detail, and be able to identify areas where opinions may diverge. A middle level of knowledge.

**Basic knowledge** — candidate must know the main points of the topic and the core literature.
2. The candidate will have a **sound** knowledge of:

   2.1. The principles of and practical applications for radiation therapy, including radiobiology, effects of ionizing radiation on cancer growth and on normal tissues.

   2.2. The fundamentals of cytology and histopathology as they relate to cancer; the candidate should display a sound knowledge of the cytologic and histopathologic interpretation of tumour types affecting domestic and non-domestic species.

   2.3. Molecular diagnostic techniques as they relate to cancer, and their interpretation

   2.4. The principles of surgery in general, and specifically in relation to oncologic disease.

   2.5. The interpretation of, and applications for, imaging modalities used in the diagnosis and staging of cancer in common domestic animals. These modalities include, but are not limited to radiology, ultrasonography, myelography, computed tomography (CT) and positron emission tomography – computed tomography (PET - CT), magnetic resonance imaging (MRI) and nuclear scintigraphy.

   2.6. The pathophysiology of organ dysfunction and the principles of systemic disease as relevant to the discipline of oncology in common domestic animals.

   2.7. The comparative aspects of veterinary and human oncology.

   2.8. The use of laboratory animals in cancer research, including investigation of fundamental cancer biology, and drug discovery and development.

3. The candidate will have a **basic** knowledge of:

   3.1. The aetiopathogenesis, epidemiology, pathology, diagnosis, and clinical management measures for common cancers of production animals, horses and non-domestic vertebrates.

   3.2. The aetiopathogenesis, epidemiology, pathology, diagnosis, and clinical management measures for oncological diseases of domestic pets including but not limited to rodents, ferrets and birds.
4. The candidate will be able to do the following with **detailed**\(^2\) expertise:

4.1. Recognise, investigate and evaluate complex oncologic diseases and paraneoplastic syndromes.

4.2. Formulate sound, rational approaches to the clinical management of complex oncologic diseases and paraneoplastic disease conditions.

4.3. Evaluate and incorporate new scientific information relevant to the practise of veterinary oncology.

4.4. Administer cytotoxic chemotherapy with due regard to the safety of the patient, medical personnel and patient caregivers.

4.5. Biopsy multiple tissue types using appropriate techniques including fine needle aspiration and cutting needle core samples, with and without imaging guidance; bone marrow biopsy and aspiration; thoracic, abdominal, and pericardial centesis.

4.6. Communicate effectively with clients, referring veterinarians and peers to provide high-quality care for animals with the most efficient use of resources in a manner that is responsive to the owner’s needs and wishes.

4.7. Advance knowledge in veterinary oncology through clinical innovation, research and publication.

4.8. Enteral nutrition tube placement.

4.9. Partial and total parenteral nutrition.

5. The candidate will be able to do the following with **basic** expertise:

5.1. Endoscopy of the respiratory, alimentary and genitourinary tracts.

5.2. Cerebrospinal fluid collection.

---

\(^2\) **Skill levels:**

**Detailed expertise** — the candidate must be able to perform the technique with a high degree of skill, and have extensive experience in its application. The highest level of proficiency.

**Sound expertise** — the candidate must be able to perform the technique with a moderate degree of skill, and have moderate experience in its application. A middle level of proficiency.

**Basic expertise** — the candidate must be able to perform the technique competently in uncomplicated circumstances.
EXAMINATIONS
Refer to the Fellowship Candidate Handbook, Section 5. The Fellowship examination has four separate, autonomous components:

1. Written Paper 1 (Component 1)
   Principles of the Subject (four hours)

2. Written Paper 2 (Component 2)
   Applied Aspects of the Subject (four hours)

3. Practical Examination (Component 3)
   Practical (two hours)

4. Oral Examination (Component 4)
   Oral (two hours)

The written examination will comprise of two separate four-hour written papers taken on two consecutive days. There will be an additional 20 minutes perusal time for each paper, during which no writing on the examination paper is permitted. In each paper you are provided with eight (8) questions to answer, worth 30 marks each, giving a total of 240 marks per paper. There is no choice of questions. Questions may be long essay type or a series of small sub-questions. Marks allocated to each question and to each subsection of questions will be clearly indicated on the written paper.

Written Paper 1:
This paper is designed to test the candidate’s knowledge of the principles of oncology as described in the Learning Outcomes. Answers may cite specific examples where general principles apply, but should primarily address the theoretical basis underlying each example.

Written Paper 2:
This paper is designed to a) test the candidate’s ability to apply the principles of oncology to particular cases, problems or tasks and b) test the candidate’s familiarity with the current practices and current issues that arise from activities within the discipline of oncology in Australia and New Zealand.

Practical Examination:
The practical examination is designed to test practical aspects of the learning Objectives. To pass this examination, candidates must be able to discuss complex case presentations and interpret the results of diagnostic tests. Candidates must demonstrate deep understanding and practical application of equipment used in oncology. Written answers will be required. No perusal time will be given for the practical exam. The practical will consist of a series of six (6) questions with sub-questions, equating to a total of 120 marks. Marks allocated to each question and to each sub-section will be clearly indicated on the written paper. Diagnostic imaging studies (including radiographs, ultrasound images, CT and MRI), photographs of
cytology and histopathology slides, clinical pathology test results, ECGs and photographs of gross tissue specimens or animals are likely to be used during this examination.

**Oral Examination:**
The oral examination is designed to test practical aspects of the Learning Objectives. To pass this examination, the candidate must be capable of justifying their views in a professional and scientific manner, on important and controversial topics in Oncology. Candidates may be asked to discuss detailed case material. Six (6) cases are presented with supporting questions asked verbally in a face-to-face setting. The oral examination has a total of 120 marks with each case allocated 20 marks. Diagnostic imaging studies (including radiographs, ultrasound images, CT and MRI), photographs of cytology and histopathology slides, clinical pathology test results, ECGs and photographs of gross tissue specimens or animals are likely to be used during this examination.

**TRAINING PROGRAMS**
Refer to the *Fellowship Candidate Handbook*, Section 3.3.

**TRAINING IN RELATED DISCIPLINES**
Refer to the *Fellowship Candidate Handbook*, Section 2.4.2.

Candidates for Fellowship in Veterinary Medical Oncology must spend supervised time in each of the related disciplines training as per the following:

- **Radiation Therapy** (80 hours, two weeks) with a veterinary or human radiation oncologist to discuss clinical management of patients receiving radiation therapy, radiation planning, dosimetry, and physics related to clinical radiation therapy.
- **Diagnostic Imaging** - radiology, ultrasonography, CT, MRI and others as available (80 hours, two weeks)
- **Small Animal Surgery** (80 hours, two weeks) including the surgical management of patients being treated for cancer.
- **Small Animal Medicine** (80 hours, two weeks) including the medical management of patients with diseases other than cancer that might be encountered during oncology practice
- **Diagnostic clinical cytology** (40 hours, one week)
- **Surgical histopathology** (40 hours, one week)
- **Elective discipline e.g. molecular oncology, molecular genetics and diagnostics** (80 hours, two weeks)

The TRD proposal and report templates can be found on the College website under Fellowship – Fellowship Forms.
EXTERNSHIPS
Refer to the Fellowship Candidate Handbook, Section 2.4.1.

ACTIVITY LOG SUMMARY
The Candidate must document, within the Activity Log Summary, a minimum of 500 cases over the training period. Cases suitable for inclusion are those where the candidate is the primary clinician performing the majority of the clinical procedures and client communication on the case. Revisit appointments on the same case for the same presenting problem are not to be entered separately in the Activity Log Summary. Of the 500 cases, a minimum of 100 cases must be dogs and a minimum of 100 cases must be cats. Candidates must also manage at least 100 cases in each of the following categories for any species;

- Round Cell Tumours
- Epithelial Tumours
- Mesenchymal Tumours

The Activity Log Summary (ALS) should be recorded using the template in Appendix A.

PUBLICATIONS
Refer to the Fellowship Candidate Handbook, Section 2.10

RECOMMENDED READING LIST
The candidate is expected to research the depth and breadth of the knowledge of the discipline. This list is intended to guide the candidate to some core references and source material. The list is not comprehensive and is not intended as an indicator of the content of the examination.

Textbooks: Essential
Textbooks: Suggested

1. Radiobiology for the radiologist Hall, 7th edition 2012
11. TNM Classification of Tumours in Domestic Animals, LN Owen 1980,

Journals: Essential

1. Veterinary and Comparative Oncology
3. American Journal of Veterinary Research.
6. Veterinary Pathology
8. Veterinary Radiology and Ultrasound
10. Australian Veterinary Journal.

Journals: Suggested

1. Veterinary Surgery.
2. Veterinary Immunology and Immunopathology
3. Veterinary Clinical Pathology
5. Compendium on Continuing Education for the Practising Veterinarian
8. Journal of the National Cancer Institute.
10. Nature Reviews Cancer
11. Nature Reviews Clinical Oncology
12. The Oncologist
13. Veterinary Clinical Pathology
14. BMC Veterinary Research
15. Topics in Companion animal medicine

**Journals: Comparative.** Candidates are responsible for articles on veterinary oncology published in the human literature and review articles discussing concepts in cancer biology and general therapeutic strategies. Suggested journals

1. Nature
2. Cell
3. Science
4. Cancer
5. New England Journal of medicine
6. Clinical Cancer Research
7. Nature reviews: Cancer
8. PLOS one

**Additional Suggested Reference Sources:**

**Veterinary Oncology**
Proceedings of the Veterinary Cancer Society

**Formulary**

**Physiology**

**Immunology**

In addition, the candidate should have ready access to texts detailing Dermatology, Gastroenterology, Endocrinology, Cardiology, Infectious Diseases, Clinical Pathology, Diagnostic Imaging, Nutrition, Urogenital diseases, Toxicology and Neurology. Choice of text should be discussed with your Supervisor.
Other Recommended Sources of Study Material
Seminar series at major hospitals and research centres.
Oncology rounds and Morbidity and Mortality seminars at major hospitals.

FURTHER INFORMATION
For further information contact the College Office

Telephone: International +61 (07) 3423 2016
Fax: International +61 (07) 3423 2977
Email: admin@anzcvs.org.au
Web: www.anzcvs.org.au
Postal Address: Building 3, Garden City Office Park, 2404 Logan Road
EIGHT MILE PLAINS QLD 4113 Australia
### APPENDIX A.1
Activity Log Summary

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>Minimum number of cases required</th>
<th>AUG</th>
<th>SEPT</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>Sub-Total</th>
<th>Previous Total</th>
<th>Total to date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ROUND CELL TUMOURS</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma Cell Neoplasm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mast Cell Tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canine Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feline Lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epitheliotropic lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukaemias and Myeloproliferative Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transmissible Venereal Tumour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histiocytic sarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (list type below)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### APPENDIX A.2
Activity Log Summary
Month of the Program

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>Minimum number of cases required</th>
<th>AUG</th>
<th>SEPT</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>Sub-Total</th>
<th>Previous Total</th>
<th>Total to date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPITHELIAL TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumours of Skin and Subcutaneous tissue</td>
<td></td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salivary Glands</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oesophageal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exocrine Pancreas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intestinal Tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perianal Tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Larynx and Trachea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine Pancreas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Endocrine System</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Reproductive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mammary Gland</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male Reproductive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Tract</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous system</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thymoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (list type below)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## APPENDIX A.3
### Activity Log Summary

<table>
<thead>
<tr>
<th>Month of the Program</th>
<th>Minimum number of cases required</th>
<th>AUG</th>
<th>SEPT</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUNE</th>
<th>JULY</th>
<th>Sub-Total</th>
<th>Previous Total</th>
<th>Total to date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CATEGORY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesenchymal Tumours</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other skeletal tumour</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemangiosarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Soft-tissue sarcoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mesothelioma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other (list type below)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>